Skip to Main Content

South Carolina life Sciences

  • sam patrick posted an article
    Zverse adding to capabilities with new product offerings see more

    Compliments Columbia Regional Business Report

    Columbia-based digital manufacturing solutions company ZVerse Inc. has launched new technology that creates 3D computer-aided design files from 2D technical drawings, cutting some project times by as much as half.

    The automation-assisted conversion generates a rapid 3D conversion project quote, then creates 3D manufacturing files that can be stored in a digital library, allowing field and repair technicians to quickly access the files and manufacture parts from anywhere, according to a news release from ZVerse.

    “ZVerse has been doing this work for years, converting 2D files to 3D through our on-demand design services,” company president David Craig said in the release. “We know the areas where you can drive automation and drive the biggest impact in workflow. We have also learned that the greatest time spent in the conversion process can be automated and we now have automated those steps. We are committed to driving even more types of automation in and around this critical business need.”

    Project times can be reduced by an average of 35% to 50% with the elimination of the need to re-draw part geometries at current manufacturing software standards, the company said.

    The advancement will address the lack of 3D digital files that is an obstacle to digital manufacturing and on-demand maintenance, repair and overhaul part production at scale, according to the release. Manufacturing engineers and industrial designer can more quickly convert legacy files, resulting in time and cost savings while improving geometric accuracy.

    The service will also reduce equipment downtime, reduce production costs and allow ZVerse customers to carry less inventory, the company said.

    Founded in 2013, ZVerse shot to national prominence last year with the development of its ZShield Flex face shield, which was named an Innovation by Design Awards winner by business magazine Fast Company.

  • sam patrick posted an article
    South Carolina featured in JD Supra article see more

    South Carolina has long been known for its colorful history, beautiful beaches and vibrant tourist industry.  In recent decades, it has also come to be well known for its high-tech manufacturing with the likes of BMW, Boeing, Honda, Michelin, Samsung and Volvo, all locating large manufacturing facilities throughout the State. What you might not know is that South Carolina is also home to another rapidly growing high-tech industry—the Life Sciences industry.

    The term Life Sciences is generally used to include companies in the fields of biotechnology, pharmaceuticals, biomedical technologies, life systems technologies, nutraceuticals, cosmeceuticals, food processing, environmental, and biomedical devices. The Life Sciences industry also includes organizations and institutions that devote the majority of their efforts in the various stages of research, development, technology transfer and commercialization, as well as the companies who support these entities.

    According to SCBIO, the trade association which represents the Life Sciences industry in South Carolina, there are over 700 companies and businesses actively engaged in the Life Sciences industry in South Carolina and at least one Life Sciences organization is located in 42 of the State’s 46 counties. The economic impact of the Life Sciences industry is approaching $12 billion per year and is continuing to increase, according to a recent study. It is also estimated that the Life Sciences industry has created over 40,000 high paying jobs in South Carolina over the last several years, with an average annual salary of over $70,000.

    The Life Sciences industry in South Carolina is very diverse.  It includes companies ranging from small startups focusing on developing new technology like Okra Medical, to a unique genetic clinical and research institution like Greenwood Genetic Center, which has been serving the State for decades, to large established companies like Nephron Pharmaceuticals. Nephron is a pharmaceutical manufacturer and cGMP compliant 503(B) Outsourcing facility, and a global leader in the manufacture of generic respiratory medication that has rapidly expanded its manufacturing capacity and services over the last seven years. Nephron is owned and led by Lou Kennedy, whose vision and leadership have spurred the Company’s growth and success and have also made her one of the State’s most important business leaders, as well as an important thought leader in the Life Sciences industry.

    South Carolina is a pro-business state that has worked diligently to attract large companies looking for a friendlier business climate from a tax and regulatory perspective. An additional driver for the growth of the Life Sciences industry is the existing ecosystem for Life Sciences, which is supported by the State’s three major research universities: University of South Carolina, Medical University of South Carolina and Clemson University as well as over ten additional universities and colleges in the State - from Furman University with its innovation program and nationally recognized chemistry department, to Newberry College launching new curriculum and a degree focused on pharmaceutical manufacturing. These universities and colleges further validate the increasing depth of the existing ecosystem and the positive impact it will have on strengthening the talent pool available to the Life Sciences industry. Other factors contributing towards this growth are the efforts of the South Carolina Department of Commerce and the South Carolina Research Authority, the strong system of hospitals and health care systems within the State, the support of various economic development alliances, the State’s expanding technical college system, the support of elected officials and the growth and leadership of SCBIO over the last several years.

    SCBIO has spearheaded a series of joint private / public initiatives to promote the growth of the Life Sciences industry in South Carolina. These efforts include promoting statewide economic development strategies to attract Life Sciences companies to locate or relocate in South Carolina and consistently promoting and strengthening the existing ecosystem which allows established South Carolina Life Sciences organizations to collaborate, grow and flourish. In addition to its economic development efforts, SCBIO has integrated its efforts with the broader mission to transform and positively impact healthcare as evidenced by its unique alliances forged with the South Carolina Hospital Association, several large health systems and large payers like Blue Cross Blue Shield of South Carolina.  For the past four years, SCBIO has been led by its CEO, Sam Konduros. Konduros has experience with economic development, operations of Life Sciences companies, developing start-up companies and most importantly—developing and implementing an ambitious strategic plan for the Life Sciences industry. During his time at SCBIO, Konduros has assembled a talented team.  His vision and energy have fueled a rapid growth in membership and engagement and an increased in awareness and support for the Life Sciences industry across the State. Under his leadership, SCBIO significantly expanded its membership and quadrupled its revenues, while at the same time establishing itself as a powerful force for economic development and creating a new platform for Life Sciences companies to collaborate on innovations and research. Earlier this month, Konduros announced his departure from SCBIO to serve on the Board of Vikor Scientific, another successful company within the Life Sciences space in South Carolina that is rapidly expanding. He will also serve as CEO of a new health innovation company powered by artificial intelligence (AI) and blockchain technologies focusing on science personalized medicine strategies that will be a part of Vikor Scientific’s expanding portfolio of companies. SCBIO is conducting a national search for Konduros’ replacement and there is no doubt that the association and its members will continue to benefit from the momentum created over the last four years as it continues to push the Life Sciences industry forward.

    The global COVID-19 pandemic presented a profound challenge to the Life Sciences industry as it disrupted the way business was conducted. The Life Sciences industry in South Carolina stepped up to these challenges and turned them into opportunities. Many Life Sciences companies pivoted from their existing strategic plans to address the needs of the State and Nation by providing assistance in key areas that became critical during the pandemic. Companies like Nephron Pharmaceuticals, Vikor Scientific, KIYATEC, Premier Medical Lab Services and others offered much needed expanded COVID-19 testing services inside and outside South Carolina. Others such as ZVerse, a digital manufacturing company, modified its business model to become one of the largest producers of reusable face shields for use during the pandemic and beyond. Over the last 12 months, they have produced millions of these reusable facemasks and have been recognized throughout the country for their efforts. Rhythmlink International, a medical device leader, donated thousands of masks and personal protective equipment (PPE) to hospitals and other healthcare providers across South Carolina.  In addition, Milliken & Company boosted its production of biosmart fabrics used in scrubs and lab coats, which uses chlorine bleach-activated technology and molecular engineering to kill up to 99.9% of the bacteria and viruses it touches. Headquartered in Greenville, Vitalink Research was selected by Moderna to run its Phase III vaccine clinical trial, demonstrating national confidence in Life Sciences research operations in South Carolina. These are just a few examples of how South Carolina Life Sciences companies responded to the challenges of the COVID-19 pandemic and highlight why the Life Sciences industry is one of the fastest growing segments of South Carolina’s economy.

    The future of the Life Sciences industry is bright in South Carolina.  South Carolina has become an attractive place to develop and expand Life Sciences companies and there is great leadership within these companies. The rapid growth of Life Sciences is becoming more apparent to the public and media. In February 2021, Governor McMaster proclaimed February 15-19 as South Carolina Life Sciences Week in the Palmetto State.  Our Life Sciences companies are leading the discussions of how to bring more Life Sciences manufacturing back to the U.S, including to South Carolina, and how to develop a domestic source of PPE and other parts of the supply chain. There is also increased collaboration on leveraging increased use of technology like telehealth and digital health to deliver health care services to rural and less developed areas using technology developed and perfected in South Carolina. SCBIO is also leading an effort to expand and improve the workforce to support Life Sciences companies.  All signs point to a very bright future for the Life Sciences industry and South Carolina is just beginning to see the benefits of this growth and development.

     Send  Print  Report

  • sam patrick posted an article
    Former SCBIO exec Sam Konduros to lead KOR Medical see more

    Former SCBIO CEO Sam Konduros named President and Chief Executive Officer

    of new Vikor Scientific health innovation company

     

    CHARLESTON, SOUTH CAROLINA – May 4, 2021 – Continuing its rapid expansion as one of South Carolina’s fastest growing life sciences and healthcare firms, Charleston-headquartered Vikor Scientific announced that it is launching health innovation company KOR Medical “to set a new industry standard in the arena of personalized clinical cannabis to benefit patients afflicted with diseases ranging from epilepsy to cancer, and to help alleviate the nation’s opioid addiction crisis.” 

    According to KOR Medical Managing Partners and Vikor Scientific Co-Founders Scotty Branch and Shea Harrelson, the company is exploring locations nationwide for its initial state-of-the-art, multi-million-dollar operation.  

    “KOR Medical will be a highly innovative organization that will bring a new blueprint and novel value proposition to the national clinical cannabis marketplace, powered by an AI and blockchain supported seed to sale platform,” said Mr. Branch.  “Coupled with a relentless commitment to personalized medicine and rigorous compliance and purity, KOR will focus on providing clinicians with the tools and data they need to support leading-edge treatment protocols for the needs of each unique patient.”

    In addition to former South Carolina Biotechnology Industry Organization (SCBIO) chief executive Sam Konduros, a seasoned business leader and attorney who will serve as president and CEO, KOR Medical is also onboarding four senior executives that bring multi-disciplinary expertise and experience in the clinical cannabis industry – including Joseph Strauss, who will serve as COO and executive vice president.  Mr. Strauss brings more than a decade of immersive experience in the industry across multiple states to KOR, including Oregon, California, Colorado, and Florida.  Other corporate appointees championing sales and marketing, cultivation and innovation, and government and legal affairs will be announced in early Summer. 

    “Mr. Konduros will lead all aspects of the company’s business and serve on the board of directors of both KOR Medical and Vikor Scientific to provide insights regarding the strategic direction of our portfolio of companies as we expand in the US and globally,” said Mr. Branch.  “Sam is the epitome of a world class CEO.  We look forward to watching him execute our mission with the support of an extraordinary executive team who will enable KOR Medical to achieve its vision to help transform healthcare.” 

    Armed with a comprehensive business plan and finalization of its laboratory-grade indoor growing facility design, KOR Medical is currently forging key industry and business partnerships with numerous entities with established track records in the cannabis industry.  KOR Medical expects to confirm its initial US location of operations by mid-Summer 2021, with the site becoming a model for future expansion across the nation.  KOR is planning its initial product launch during 2021, followed by full-scale production in 2022. 

    Visit KOR Medical at www.kormedical.com and Vikor Scientific at www.VikorScientific.com.

  • sam patrick posted an article
    Trio collaborate to turn back COVID tides see more

    It was not long ago when we all witnessed demand for critical Personal Protection Equipment (PPE) far outstripping supply on the front lines of the COVID-19 battle.

    While this story line is now receding in our memory, it became a rare instance in South Carolina based on extraordinary efforts from entities like Humimic Medical, South Carolina Biotechnology Organization (SCBIO), and South Carolina Manufacturing Extension Partnership (SCMEP).  Not only did these groups address frontline workers, but they also addressed the critical PPE needs of organizations a few layers back from the front lines – such as non-profit community outreach groups, church programs, and workforce development groups.

    Humimic Medical teamed up with SCBIO and SCMEP to help these organizations and others out. Leveraging the broad network of SCBIO and connected distribution channels of SCMEP, Humimic Medical donated thousands of face shields to organizations across South Carolina which desperately needed quality, made-in-the-USA protective equipment.

    “Helping the ‘little guys’ has always been part of my DNA, I guess,” commented Joel Edwards, CEO of Greenville’s Humimic Medical. “We started in a garage 10 years ago and grew from there. Organizations willing to support the little guy like us along the way helped us tremendously in getting to where we are today. So having the opportunity to give back and help others who may not be first in line to receive PPE supplies just felt right.”

    Humimic Medical does not typically produce PPE. However, as they continued to become more deeply entrenched in the collaborative life science ecosystem network that SCBIO has forged in the Palmetto State (which includes groups like SCMEP), they realized they could join the fight against COVID-19. Early in the pandemic, Humimic Medical shifted some of its engineering and manufacturing resources from their medical trainer product lines to help supply PPE where it was needed most.

    There was one problem though. Humimic Medical didn’t have the established distribution channels for PPE in South Carolina. That’s where SCBIO’s connection to SCMEP came into play. Organizations like SCMEP also serve as key players in South Carolina’s connected, collaborative, and growth-oriented network. SCMEP’s mission of helping state organizations improve their competitiveness, performance, and profitability provided a perfect backdrop for Humimic Medical to connect to organizations around our state who still desperately needed PPE supplies like face shields.

    “SCMEP always prides itself in being a strategic resource for companies in our State”, shared Chuck Spangler, President of SCMEP. “We’re grateful we could leverage our network in collaboration with SCBIO and Humimic Medical to serve organizations in need.”

    Added SCBIO Interim CEO Erin Ford, whose team was able to rapidly connect Humimic with key contacts to deliver the new face shields where they are needed most, “We continue to live our mission of being the life sciences industry convener, and that’s more important than ever right now.”

    “Organizations SCBIO and SCMEP continue to be invaluable assets in our State,” said Edwards.  “The rich, collaborative networks these kind of groups create are what will continue to make South Carolina a leader in new business development.”

     

    About Humimic Medical:  

    Humimic Medical is a rapidly growing medical trainer and synthetic gel manufacturing company based in Greenville, SC. The company is driven by innovative product design, world-class customer service, and fueled by robust collaborative partnerships with universities and healthcare providers. Humimic Medical utilizes its proprietary synthetic gel blend to more closely represent human tissue elasticity and maintain recyclable/reusable qualities that no other product line currently offers delivered at a significantly lower price point than any existing products.

    About SCMEP:

    SCMEP is a private, non-profit group that serves as a proven resource to South Carolina businesses, providing them with a range of innovative strategies and solutions. An affiliate of the National Institute of Standards and Technology (NIST), SCMEP operates under the US Department of Commerce to promote innovation and industrial competitiveness. SCMEP uses a strategic, hands-on, partnering approach to help South Carolina companies improve their competitiveness, performance, and profitability in today’s increasingly demanding global economy.

  • sam patrick posted an article
    New Jersey firm expands into South Carolina see more

    Courtesy of Charleston Regional Business Journal

    A biopharmaceutical company has opened a Goose Creek facility as part of its goal to establish 10 or more collection centers around the country by 2024, the company said in a news release..

    New Jersey-based ADMA Biologics Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.

    Adam Grossman, president and CEO, said South Carolina and Gov. Henry McMaster expressed strong support for opening the new facility.

     “The state’s impressive infrastructure and skilled workforce create a terrific foundation for ADMA to safely collect and process plasma, and we look forward to continuing to grow our operations in the state now and in the coming years,” he said in a statement.

    McMaster was on hand April 23 for a ribbon cutting ceremony, which Grossman said helped create an even stronger beginning for the company.

    Beneath the corporate umbrella, ADMA has seven plasma collection facilities at various stages of approval and development. The Lowcountry plasma center, located at 214 Saint James Ave., is the newest and is projected to need up to 50 health care workers at full capacity.

    “Securing raw material plasma supply has never been more important than it is today, and we believe the series of recent acquisitions of plasma collection facilities validates this scarcity value,” Grossman said.

    The Goose Creek center includes automated registration, high-tech collection equipment designed to shorten the donation process, free WiFi and individual flat-screen TVs at each donor station and trained, certified staff.

    The company is on track to achieve its 2024 goal and Grossman said the expansion will support ADMA’s goal of producing “quarter-over-quarter revenue growth throughout 2021 and beyond.” The Goose Creek operations also will help ADAM create a fully integrated and self-sufficient plasma supply chain, ensure continuity of product supply and generate asset value for shareholders, the company said.

    ADMA plans to file an application for a biologics license and anticipates a standard 12-month BLA review period by the Food and Drug Administration.

    Until then, ADMA is allowed to collect plasma donations on site. Following the FDA’s approval, the company can then use the collections for further use in the manufacturing of life-saving therapies.  

  • sam patrick posted an article
    Applications pipeline opened in four new areas see more

    Flywheel’s early-stage investment and accelerator program announced today it is expanding in regions ranging from the North Carolina Core to Upstate South Carolina. New Ventures opened applications this month to four separate application pipelines and areas of focus through June 7, 2021.

    The expanded accelerator program offering is coupled with a fourfold expansion of the corollary investment funds. “Our ability to replicate the New Ventures program as we expand our network of innovation centers along the I-85 corridor is based on the success of the program over its first five years,” says Peter Marsh, a cofounder of Flywheel and administrative member of the New Ventures LLCs.

    “As we expand geographically, the regions we serve all find that access to inception- and early-stage capital fills a gap in the entrepreneurship ecosystems and helps stimulate formation and attraction of scalable technology companies,” he continues.

    Page Castrodale, the Executive Director of Economic Development for Cabarrus County where Flywheel just opened it’s third location adds, “We believe that economic development is just as much about organic job creation as it is about recruiting new companies to our community. The expansion of the New Ventures program to our region will stimulate economic development at the earliest stages, and we know the impact of that will be immeasurable.”

    Flywheel’s affiliated Foundation administers the accelerators using their Learning Management System to deliver the core curriculum and subject matter experts to deliver insights in the market verticals. The development of the hybrid developmental model was in response to the pandemic.

    “The silver lining from 2020 is that it forced us to be innovative with a virtual cohort experience,” says Adrian Smith, Executive Director of the Flywheel Foundation. “That enables us to run multiple accelerators simultaneously, and the participating companies gave us the best ratings out of any year so far.”

    The accelerators will run from August 3 through Demo Days on October 28-29.  Companies accepted into the program also enjoy a residency at Flywheel innovation centers during the 13-week program and for 3 months following.

    “The accelerator program offering is diverse and a reflection of the knowledge assets in the regions served as well as the economic and social impact mission of the Foundation,” says Adrian. Details on the four 2021 accelerators can be found at https://www.newventuresnc.com/. New Ventures is conducting information session for investors and founders throughout the application window and the dates are listed on the website.

    • Health, Wellness, and Nutrition – Focus is on the regional healthcare knowledge assets and partnering with the North Carolina Research Center in Kannapolis and the NC Food Innovation Lab.
    • AgTech - Greenworks of Lexington is a 64,000 sq. ft. agricultural lab and research facility with a 20,000 square foot Flywheel coworking innovation center opening in 2022. Flywheel is  partnering with SouthXCapital and anchor AgTech tenants on the accelerator.
    • B2B Software with focus on SaaS – This accelerator pulls participation from all of Flywheel’s innovation center locations and invites tech companies that intersect with our strongest industries and regional market verticals.
    • The Come Up Accelerator - Partnering with HUSTLE Winston-Salem to offer an accelerator for Black and Brown founders. Flywheel Foundation has acted as a fiscal sponsor for HUSTLE since its inception.

    This is the sixth year of the New Ventures Challenge and acceleration program which has created a portfolio of 21 companies over five cohorts starting in 2016.

    “We measure our success primarily by the valuation growth in the portfolio, customer growth, and the ability of our companies to secure follow-on financing to continue to develop their organizations”, says Patrick Turner, an investor in the first three New Venture funds and a fractional CTO that advises companies in the program.

    The 21 portfolio companies have grown from New Ventures’ first five years have grown in value to a combined $43,155,110, have received over $15 million in financing, and have created over 100 new jobs.

    “Flywheel and the New Ventures program are critical resources that fill a gap that will be catalytic for our Upstate entrepreneurial community,” says Anthony Herrera, executive director of Furman University’s Institute for Innovation and Entrepreneurship.

    New Ventures is an application-based program that invests an average of $50,000 in inception-stage startups. While the program intentionally seeks out in-state startups, it also invests throughout the Southeast and beyond.

    The expanded program not only reflects Flywheel’s increased reach geographically, but has also increased diversity and inclusion as a priority, partnering with HUSTLE to run the Come Up Accelerator focused on minority founders.  

    “With the Flywheel Foundation's New Ventures curriculum coupled with HUSTLE's cultural competence and commitment to disrupting biases for Black and Brown entrepreneurs, The Come Up accelerator is well suited to help scale people, community trust, and the bottom line of minority-owned businesses”, says HUSTLE Executive Director Magalie Yacinthe.

  • sam patrick posted an article
    PMLS launches one of the nation’s largest variant surveillance initiatives see more

    The Biden Administration announced Friday a $1.7 billion investment to monitor new and emerging COVID-19 variants which could induce another pandemic wave. Concurrently, to combat these mutated strains, advanced molecular diagnostics laboratory, Premier Medical Laboratory Services announces their launch of one of the nation’s largest variant surveillance initiatives. Now conducting genomic sequencing of 6,000 specimens per day, PMLS plans to increase that number to 12,000 by May. The large amounts of data gathered by this initiative will help protect the population from a future surge and cases with increased severity of symptoms.  

    When speaking on Pfizer’s ability to adjust the vaccine for effective inoculation against the new variants, a Pfizer Executive said Saturday, “You can basically, within a couple of weeks, put a new sequence in.” In order to make these adjustments to vaccines, scientists developing them need genomic sequencing data on a large scale, like that being produced by PMLS.

    Scientific Director of Clinical Genetics for PMLS, Vidhya Narayanan commented, “Sequening information and population studies can give us vital information regarding evolution of the COVID 19 virus and transmission pattern which otherwise can go unnoticed.”

    The COVID-19 virus is structured so that inside each nucleocapsid protein is the viral genome, which over time can mutate for the virus to be more efficient at spreading and to potentially cause more severe illness than the original strain. Genomic sequencing decodes the genomes to learn about the virus and how it is evolving. Standard polymerase chain reaction (PCR) COVID-19 tests, which are most widely used for detection of the COVID-19 virus, are very specific to detecting the pathogens of the original COVID-19 strain. Next generation sequencing is able to detect new pathogens so that epidemiologists can study viral genome mutations to understand how they affect the viral characteristics of COVID-19 and to determine future health implications the novel variants may cause.

    Because library prep instruments and genomic sequencers are in short supply, many laboratories spend hours conducting library prep and sequencing manually. With high throughput genomic sequencers and library prep instruments that automate the library prep and sequencing process, PMLS achieves a much higher capacity for genomic sequencing. By monitoring an exponentially higher amount of specimens, PMLS is better equipped to provide meaningful analysis with larger amounts of data and faster turnaround times for the effective surveillance of SARS-CoV-2.

    “We want to be proactive with these new variants in case any adjustments need to be made within the healthcare industry for patient care or new safety protocols need to be put into place,” said Kevin Murdock, Founder of Premier Medical Laboratory Services. “Data is the most vital piece in beating this pandemic, so we made this a top priority to aquire the most advanced sequencing equipment and top scientists to help monitor them.”

    Of growing concern, among other variants, is the Indian variant (B.1.617), which has spread to the UK and made landfall in California approximately two weeks ago. This variant is potentially the catalyst for a recent surge of cases in India and is believed to have more rapid rates of transmission than the original strain like the UK variant (B.1.1.7) that is estimated 50 percent more than the standard form of SARS-CoV-2 which is also been shown to cause higher mortality rates. (1,2)

    Other current known variants:

    • Brazil (P.1)
    • South Africa (B.1.351)
    • California (B.1.427/B.1.429)
    • New York (B.1.526)

    The high-volume sequencing being conducted at PMLS follows suit with COVID-19 testing solutions they have provided as a laboratory with one of the highest testing capacities in the nation. Their ability to test over 300,000 specimens per day for COVID-19 paired with their rapid turnaround of accurate results is why they are the chosen laboratory to conduct testing for Human Health Services surge sites, large organizations, schools, athletic teams, and state health departments across the US.

    According to the CDC, genomic surveillance can help detect variants with:

    • Ability to spread more quickly in people
    • Ability to cause either milder or more severe disease in people
    • Ability to evade detection by specific diagnostic tests 
    • Decreased susceptibility to therapeutics that employ monoclonal antibodies
    • Ability to evade natural or vaccine-induced immunity (3)

    Sources:

    1. Harvard Magazine https://harvardmagazine.com/2021/01/covid-19-variants
    2. Nature Research Journal: https://www.nature.com/articles/s41586-021-03426-1
    3. CDC: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance.html?CDC_l.html

    For more information, please visit www.premedinc.com/ngs or call 1.866.800.5470.

     

    ABOUT PREMIER MEDICAL LABORATORY SERVICES

    Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women’s Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and a first of its kind predictive genetic test for type II diabetes, DiabetestPredict. For more information, please visit www.PreMedInc.com

  • sam patrick posted an article
    Minority med students get a boost see more

    Courtesy of GSA Business Report

    Minority medical students will have a chance to take advantage of a $45,000 annual scholarship at the University of South Carolina School of Medicine Greenville for the next 10 years thanks to a recent grant from The BlueCross BlueShield of South Carolina Foundation and the Levi S. Kirkland Sr., M.D. Society.

    The total $3.7 million Levi S. Kirkland Sr., M.D. grant will ultimately support 21 students during four years of study at the school with the intention of boosting numbers of underrepresented populations in the field. Patients are 19 to 26 times more likely to seek care from a physician who looks like them and has similar life experiences, according to the news release.

    “The Levi S. Kirkland Sr., M.D. Society is a business resource that focuses on mentorship, sponsorship and engaging the community,” Dr. Frank Clark, president of the Levi S. Kirkland Sr., M.D. Society, said in the news release. Clark is clinical assistant professor at the University of South Carolina School of Medicine Greenville and medical director and division chief for adult inpatient and consultation-liaison services at Prisma Health−Upstate. “It’s vitally important, as we serve our communities, that we have a diverse physician workforce.”

    The 10-year grant, named after the first Black physician to work in the Greenville Health System, now known as Prisma Health, is the longest-running grant in the foundation’s history and was gifted after the University of South Carolina School of Medicine accepted its most diverse student population yet with a 24% minority cohort, the release said.

    The school projects that number to rise to 26% for the 2021 class, according to the release.

    “We are thrilled at the opportunities that this grant will provide for our students,” Dr. Marjorie Jenkins, school dean and chief academic officer at Prisma Health−Upstate, said in the release. “This generous grant from the foundation is an important investment in our students and a testament to the excellent medical education we provide to future physicians for the Upstate and across South Carolina.”

    Students who receive the scholarship must agree to practice medicine in the Palmetto State for four years.

    “One of the biggest worries of medical school is finances, tuition and living expenses,” Dillon Isaac, a medical student at the school and past scholarship recipient, said in the release. “Because of this scholarship, all of my efforts can go into studying medicine, addressing health care disparities, and looking into social determinants of health. Altogether, this will help me give my overall best toward patient care and give back to the community that raised me. With that, I’m extremely excited to share I’ll be continuing my medical training as an internal medicine-pediatrics resident in the Upstate. I’m so excited to follow in the footsteps of the physicians that continuously support and inspire me.”

  • sam patrick posted an article
    Erin Ford named SCBIO Interim CEO as Konduros accepts private sector position see more

    Exiting CEO credited with reinvigorating organization, building team and investor base to “take South Carolina life sciences to an entirely new level”; SCBIO to conduct national search for new CEO

     

    SOUTH CAROLINA – April 7, 2021SCBIO Chief Executive Officer Sam Konduros – who has led the rejuvenation of South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, innovating and growing the life sciences industry in the Palmetto State for four years – is stepping down from his current role in May to pursue “an extraordinary private sector opportunity in the life sciences and healthcare space,” the organization’s Board of Directors has announced.

    Konduros is departing SCBIO to serve on the Board of Directors of Charleston-headquartered Vikor Scientific, and as Chief Executive Officer of a new health innovation company focused on delivering a novel blueprint to the healthcare marketplace, powered by AI and blockchain technologies and focused on science-based personalized medicine strategies to solve some of the nation’s most pressing healthcare challenges.  The soon-to-be identified organization will be revealed in May 2021 and will be part of the Vikor Scientific growing portfolio of companies.  Vikor Scientific, led by co-Founders Scotty Branch and Shea Harrelson, is a prominent national brand among SCBIO’s Board and 140+ investors and organizational members, that has experienced explosive growth over the past 3 years.

    Konduros is working closely with SCBIO’s board leadership on a carefully designed transition strategy.  SCBIO’s world class board – comprised of top executives from industry, economic development, healthcare, research, government and higher education – will begin the search for Konduros’ successor immediately with SCBIO Executive Vice President and Chief Operating Officer Erin Ford assuming day-to-day responsibilities and reporting to the board once Konduros officially departs in early May.

    “Sam Konduros has been a force – for economic development, for life sciences and for the long-term prosperity of South Carolina,” said SCBIO Board of Directors Chair Lou Kennedy, also the CEO of Nephron Pharmaceuticals.  “It has been an honor to work with him, he has made a remarkable impact on this organization, and he leaves it better than he found it, as one of the most influential associations in the state. We thank Sam for the service and sacrifice he has given to SCBIO, and we wish him all the best.”

    As Executive Vice President and Chief Operating Officer, Ms. Ford has served as primary lead for SCBIO’s business operations and finances, championing investor relations and existing industry strategies, and spearheading integrated marketing initiatives.  She has managed the majority of the organization’s day-to-day requirements since joining SCBIO in 2017.  She will assume the role of Interim CEO of SCBIO effective May 1st.

    “Serving as President and CEO of SCBIO has been a true honor, and one of the great highlights of my career to date.  It is bittersweet to depart in the midst of such incredible progress, but the organization has never been on more solid footing with strong finances, an amazing team, and a world-class Board of Directors to lead it forward.  I will remain committed to its success for years to come in my new role, as I directly join the beloved industry that I have striven to serve and support in recent years.  I am beyond grateful to SCBIO’s Board and to my new employer, Vikor Scientific, for the extraordinary opportunities that I’ve received,” said Konduros.

    During Konduros’ tenure, SCBIO has more than doubled membership and quadrupled revenues, implemented a strong economic development focus, and launched a new innovation platform.  It also expanded its role as the voice of the life sciences industry, implemented a surging workforce development initiative and created ongoing programs to encourage participation by women in life sciences, to support diversity-equity-inclusion initiatives and to encourage student participation in the industry.  The organization also successfully led industry and organizational pivots during the COVID pandemic.  In a recent proclamation followed by an executive order issued last week, Governor Henry McMaster has formally authorized SCBIO and the state’s Commerce Department to work together to accelerate the onshoring and repatriation of the pharmaceutical industry and vital PPE products and technologies to South Carolina.

    “SCBIO has worked diligently to help South Carolina raise its profile as an emerging leader in the life sciences,” said Ms. Ford. “Our innovative companies and exceptional workforce are drivers in strengthening this industry, and we know that the life sciences will continue to play a critically important role in our state’s economic success.  Sam has been an incredible contributor to this effort, and we intend to build on our Board’s, team’s and his vision to build, advance and grow life sciences in our state.”

    Life sciences has a $12 billion economic impact in the Palmetto State, with more than 700 firms involved and over 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental, and agricultural biotechnology products.  It also represents a significant economic development focus for the state, with strong life science recruiting initiatives led by the South Carolina Department of Commerce and other regional economic development teams.

    South Carolina life sciences has seen a near-doubling of firms and 40% increase in life sciences’ direct employment since 2017, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Joseph Von Nessen, the state's research economist and noted economic development expert with the Moore School of Business at the University of South Carolina.

    For additional information on SCBIO, please visit www.SCBIO.org.

  • sam patrick posted an article
    Life sciences company establishes diversity internship program see more

    The ISPE Foundation and Nephron Pharmaceuticals Corporation announced a partnership on the ISPE Foundation Diversity Internship Program's newest cycle to provide world-class opportunities to groups that are typically underrepresented in the pharmaceutical industry.

    Established December 2020, the pilot ISPE Foundation Diversity Internship Program received a strong response from applicants. This series with Nephron will be a 12-week experience that offers graduate and undergraduate students in their junior or senior year the opportunity to spend the summer working on priority projects for one of the fastest-growing pharmaceutical companies in the country.

    “I am delighted and honored to announce the partnership of Nephron Pharmaceuticals with the ISPE Foundation on its Diversity Internship Program,” said Antonio Moreira, PhD, ISPE Foundation Board Chair, Vice Provost, Academic Affairs, University of Maryland Baltimore County. “Over the coming years, a diverse pool of very talented students will be engaged in a variety of technologically stimulating projects under the guidance and mentorship of Nephron Pharmaceuticals scientists and engineers. These life changing experiences will inspire the interns to continue pursuing the many career opportunities that the pharmaceutical industry offers to these future leaders.”

    “We pride ourselves on two things: first, we do everything we can to make sure that everyone has a chance to achieve their dreams, and second, we utilize interns and apprentices in everything we do – they are playing key roles in our expansion and growth,” said Lou Kennedy, CEO, Nephron. “This is why I am so excited to partner with the ISPE Foundation to rollout these new internship opportunities. They represent a win-win – for participants and for our company. We are proud to invest in talented young people, and we are excited they want to invest in us. We cannot wait to get started.”

    There are currently multiple internship opportunities through the ISPE Foundation-Nephron partnership, including in the following departments:

    • Analytical Services and Formulation
    • Molecular Biology
    • Engineering

    The individuals participating in these internships will play key roles in Nephron’s ongoing projects. They will work directly with the entire Nephron team. And they will make a difference for patients across America.

    The deadline to submit is 6 May 2021. To learn more, please visit ISPEFoundation.org/Diversity-Internship-Program

    About ISPE and ISPE Foundation
    The International Society for Pharmaceutical Engineering (ISPE) is a not-for-profit association serving its 18,000+ Members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. Founded in 2017 as the philanthropic arm of ISPE, the ISPE Foundation supports education, training, and research for the advancement of innovative technologies and provides solutions to global challenges in the development, manufacture, and supply of quality pharmaceutical products for the benefit of patients around the world. To aide in this endeavor, the Foundation focuses on initiatives related to increasing the technical knowledge of the incoming workforce, fostering diversity within the industry, and supporting efforts to bring quality pharmaceutical manufacturing to new markets. Visit ISPEFoundation.org for more information.

    About Nephron Pharmaceuticals Corporation
    A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs.

    Inquiries related to the program may be directed to Foundation@ISPE.org

  • sam patrick posted an article
    FirstString Research announces new partnership with BARDA see more

    When responding to a chemical incident, mitigating long-term consequences of exposures is just as important as treating short-term injuries. BARDA and FirstString Research have partnered to repurpose Alpha-connexin Carboxyl-Terminal 1 (aCT1) eye drops as a potential medical countermeasure (MCM) against chronic eye injuries associated with sulfur mustard exposure.

    Under BARDA’s Division of Research, Innovation, and Ventures (DRIVe) Repurposing Drugs in Response to Chemical Threats (ReDIRECT) program, BARDA will provide funding for proof-of-concept studies to evaluate the therapeutic potential of aCT1 eye drops in preclinical models of sulfur mustard corneal injury. aCT1 eye drops is the second compound to be investigated as a repurposing candidate under the ReDIRECT program, a partnership between DRIVe and the Chemical, Biological, Radiological, and Nuclear (CBRN) medical countermeasures Branch.

    aCT1 is a synthetic peptide that has been shown to promote wound healing and temper pathological inflammation in the skin and eye. A topical formulation of aCT1, called Granexin® gel, is in late-stage trials (Phase 2/3) for indications of cutaneous radiation injury, cutaneous scarring from breast reduction surgery, and thermal burns.

    aCT1 eye drops decrease inflammation (a common pathological response to chemical injuries such as sulfur mustard) and may promote regenerative ocular healing. Given that aCT1 displays anti-inflammatory effects for multiple indications within the field of regenerative medicine, the therapeutic potential of an ophthalmic formulation (aCT1 eye drops) will be investigated for long-term ocular injuries caused by vesicants (blister agents), specifically sulfur mustard.

    In the aftermath of sulfur mustard exposure, acute injury to the cornea often resolves on its own within a few weeks. However, in some patients, a chronic condition may arise later once treatment stops. This delayed, recurring corneal injury, known as mustard gas keratopathy, is typically irreversible and can result in blindness. Repurposing aCT1 as an MCM against mustard gas keratopathy has the potential to improve the quality of life after chemical exposure by preventing the loss of eyesight.

    These studies will aid in establishing rapidly deployable capabilities that can be used to reduce adverse health effects following ocular exposure to sulfur mustard.

    This award is just one component of BARDA’s CBRN medical countermeasures and DRIVe’s medical countermeasures portfolios. Visit DRIVe’s ReDIRECT program to learn more.


    About FirstString Research:

    The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

    FirstString Research is an innovative biopharmaceutical company dedicated to discovering breakthrough therapies for inflammation and injury based medical conditions. The company is focused on developing and bringing to the market new therapeutic products that enable physicians to treat unmet medical needs. FirstString’s therapeutic approach aims at addressing disorders by mitigating excessive inflammation, calming the inflamed tissue, and rebooting the body’s normal injury response mechanism to enable rapid, regenerative. Learn more at https://firststringresearch.com/.

  • sam patrick posted an article
    USC adds accolades for its medical school see more

    The University of South Carolina School of Medicine Columbia is the top medical program in the country for graduates who are practicing in areas where there is a shortage of health care professionals, according to the latest U.S. News & World Report’s Best Graduate School rankings.

    The medical school’s distinction is part of the U.S. News rankings released March 30; the rankings show that UofSC is now home to more than 60 nationally ranked programs.

    Among those is the International MBA program in the Darla Moore School of Business, which retained its No. 1 ranking for the eighth consecutive year.

    “From meeting the health care needs of South Carolina’s underserved communities to preparing graduates to excel in careers in all corners of the world, these rankings demonstrate the work our faculty, staff and students do each day to improve the lives of people across the state, nation and world,” says William Tate, the university’s provost and executive vice president of academic affairs.

    The School of Medicine’s No. 1 ranking fulfills the university’s mission by providing doctors for underserved areas, sometimes referred to as “medical deserts.”

    The Columbia med school also ranks No. 45 for the number of doctors practicing in primary care specialties and No. 54 for graduates practicing direct patient care in rural areas. The School of Medicine is ranked No. 76 nationally in primary care, improving 14 spots from last year’s U.S. News rankings.

    “We are proud to be producing graduates who are committed to providing exceptional patient care to underserved communities,” says Dr. Les Hall, dean of the UofSC School of Medicine Columbia. “Our school was established to create a pipeline of quality health care professionals for South Carolina. These rankings are a clear illustration that we are achieving that mission and more.”

    The Moore School continued its reign as the highest ranked international business master’s program in the country. The International MBA has been ranked in the top three for 32 straight years.

    The university’s ranked graduate and professional programs include diverse areas of study in the sciences, humanities, technology, engineering, health sciences, law and business.

    Other highlights from the new rankings include:

     

     

    • No. 7 for school library media.
    • No. 9 for services for children and youth.
    • No. 17 for library and information studies.
    • No. 23 for criminology program.
    • No. 25 for part-time MBA.
    • No. 25 for nuclear engineering.
    • No. 25 for speech language pathology.

  • sam patrick posted an article
    Kennedy's honored for continuous service to GSSM, state see more

    The South Carolina Governor’s School for Science + Mathematics (GSSM) and its Foundation honored Lou and Bill Kennedy with the 2021 Townes Award during “Empowering STEM Leaders,” the 27th annual Townes Award Celebration, Wednesday, March 17, 6-9 p.m. at 1208 Washington Place in Columbia.

    “GSSM was honored to present the Townes Award to Lou and Bill Kennedy in recognition of their transformational leadership and commitment to empowering future generations of scientists, engineers, and innovators,” said Beth Dinndorf, executive director of the GSSM Foundation.

    “GSSM seeks out and advances our state’s most talented and motivated students,” said Danny Dorsel, GSSM Interim President and GSSM Class of 1990. “Charles Townes and Lou and Bill Kennedy are shining examples for these young minds to challenge themselves to be innovative and make a difference in our world.”

    Named for South Carolinian Dr. Charles Townes, whose visionary spirit and pioneering research led to the invention of the laser, the Townes Award recognizes individuals, businesses, and institutions that have transformed South Carolina and the world.

    “Bill and I are very deeply humbled and really excited to accept an award named in honor of an extraordinary South Carolinian who was able to achieve the Nobel Prize and the Templeton Prize, as well as many other things. This is such an auspicious group, and I’m excited to be a part of it,” Lou Kennedy said in her acceptance remarks.

    Lou and Bill Kennedy are co-owners, and Lou is the CEO, of Nephron Pharmaceuticals Corporation, a South Carolina-based company that develops and produces safe, affordable generic inhalation solutions and suspension products, including those used to treat severe respiratory distress symptoms associated with COVID-19.

  • sam patrick posted an article
    Matt Bell named to head SC Launch see more

    The South Carolina Research Authority (SCRA) has announced that Matt Bell was recently named Director of SC Launch and Executive Director of SC Launch, Inc. Bell replaces Russell Cook who resigned to focus on his recovery from a medical issue.

    A member of SCRA’s leadership team, Matt Bell is responsible for leading the strategic direction of the SC Launch program, which provides mentoring, networking, and grant funding to eligible companies that are employing new technologies within the advanced materials and manufacturing, information technology, and life science sectors. He also serves as the liaison to the SC Launch, Inc. board of directors, which makes capital investments in SCRA Member Companies that successfully complete the due diligence process. Established in 2006, SC Launch, Inc., is an independent, nonprofit corporate affiliate of SCRA.

    “Matt brings a broad background in startup creation from managing intellectual property and launching startups in academia to early-stage investing and venture capital experience. He is also an expert convener who understands how to bring the right people and resources to the table for economic development through innovation,” said Bob Quinn, SCRA Executive Director. “The SC Launch team has been accelerating the growth and success of Member Companies for many years, and Matt brings the right background and experience to lead this team as they guide our companies to becoming highly investible. We sincerely thank Russell Cook for his service to SCRA and the state, and we wish him a speedy and full recovery.”

    Prior to coming to the SCRA, Bell was managing director for Discovery Partners Institute, a University of Illinois-led initiative that leverages the state of Illinois’ university resources to drive economic development through workforce training, student immersion, and research programs. He was also a managing director and a principal with Cultivian Sandbox Venture Fund where he raised capital, managed strategic investor relationships, and managed fund activities.

    Matt Bell is a board member and advisor for Michigan State University’s state-wide, agriculture-focused translational fund, a former board member of Abcelex Technologies, and a U.S. Department of Agriculture Small Business Innovation Research grant reviewer. He earned a Master of Business Administration and a Bachelor of Science from the University of Illinois. He will be based in SCRA’s Greenville office.

    About SCRA

    https://scra.org/

    Chartered in 1983 by the State of South Carolina as a public, nonprofit corporation, South Carolina Research Authority (SCRA) fuels South Carolina’s innovation economy through the impact of its four programs. SC Academic Innovations provides funding and support to advance multi-institutional, translational research and accelerate the growth of university-based startups. SC Facilities offers high-quality laboratory and administrative workspaces for technology-based startups and academic institutions. SC Industry Solutions facilitates and funds partnerships between and among startups, industry, and academia. SC Launch mentors and funds technology-based startups that may also receive investments from SCRA’s investment affiliate, SC Launch, Inc.

  • sam patrick posted an article
    Company has processed over one million COVID tests see more

    Diversified Medical Healthcare (DMH), a holding company with four subsidiary healthcare companies, Premier Medical Laboratory Services (PMLS), CPT Medical, OnGen, and Vessel Medical, has provided leading-edge solutions to combat COVID-19 nationally, addressing supply chain gaps and infrastructure restrictions caused by the virus. Their molecular diagnostics laboratory, PMLS, became the first lab in South Carolina validated as an independent COVID-19 testing lab one year ago. Just as PMLS achieved this validation for testing shortly after the first case was reported in the US, they continue to meet demands caused by COVID-19 as they arise with their laboratory staff of over 360 employees and in-house research and development team of Ph.D. scientists. Along with large scale testing via state of the art automated lab equipment, DMH companies developed advanced software for most efficient data management, distributed customized PPE supply kits, and manufactured COVID-19 testing kits as well as viral transport medium that properly preserves specimens during transit. 

    “Since COVID-19 became a threat to our nation, we quickly streamlined our workflow, hired employees, validated various coronavirus assays, and purchased the equipment needed to test a large volume of specimens with the highest quality standards,” said Kevin Murdock founder of Diversified Medical Healthcare. “With our laboratory having one of the highest testing capacities in the nation, an in-house medical manufacturing firm, a lab equipment company, and data management software company, we feel that it’s imperative to do our part to help keep the country open and our citizens safe.”

    At this one year mark, PMLS has processed over one million (1,000,000) tests to determine COVID-19 results for patients nationwide. With their highly advanced laboratory information management system (LIMS) created by OnGen, data is communicated directly from high throughput laboratory equipment for fast, accurate storage and delivery of data to healthcare providers and patients. Many of PMLS’ lab processes are automated to allow them a testing capacity of 300,000 tests per day. With this scalability, PMLS has enabled other laboratories and testing sites to increase their testing capacity and turnaround of results with Virtual Lab. An innovative COVID-19 testing solution to overcome laboratory infrastructure restrictions, Virtual Lab allows these facilities to utilize PMLS’ fully-automated robotic workflow and team of 360 employees to largely increase their testing capacity and efficiency while bypassing the need to purchase new equipment or endure waiting time of weeks or more for shipping, installation, and validation. Along with helping other labs, hospital systems and large organizations to test more patients, Diversified Medical Healthcare has donated hundreds of thousands of masks to local law enforcement, paramedics, fire departments, hospitals, and the Shriners organization and has provided free testing to first responders during the pandemic.

    As another means to aid laboratories, healthcare systems, and large organizations in the expansion of their COVID-19 testing, Vessel Medical offers Lab in a Box, turnkey lab equipment that comes with everything needed for professional laboratory level diagnostics for COVID-19, Flu A and B, upper respiratory, STD/UTI, cancer risk screening, pharmacogenomics, and antibiotic resistance testing. Developed by leading scientists and technicians in partnership with Hamilton Company, Thermo Fisher, and Grenova, Lab in a Box enables a high capacity of onsite diagnostics for hospitals, expanding laboratories, schools, and large companies in need of quick and accurate testing results. With precision robotic instruments, lab in a box includes high throughput liquid handling along with automated, custom-programmable pipetting that decreases human error and result turnaround time.

    Another DMH company, CPT Medical, shifted their production of surgical supplies to include manufacturing of COVID-19 testing kits since the beginning of the pandemic. CPT Medical is now capable of manufacturing 60,000 test kits per day and works in conjunction with PMLS to offer customizable testing to large organizations. Some of the large organizations that PMLS has partnered with as the official COVID-19 testing lab are the United Soccer League (USL) and Division I/Division II teams in 7 collegiate conferences as well as large schools and business organizations across the US. PMLS is also the processing lab for Human Health Services surge sites and state health departments in South Carolina, Arizona, Utah, and North Carolina and is the Blue Cross Blue Shield preferred COVID-19 testing lab in Texas, South Carolina, and North Carolina. Through all of these partnerships, PMLS has continued in their reputation of delivering the most advanced testing with rapid, reliable results, and diligent customer care.

    Now, as vaccines are administered and restrictions on social distancing are being lifted, PMLS is conducting a critical large scale genomic sequencing for the surveillance of new COVID-19 variants, taking proactive measures so that a future surge of a mutated Sars CoV-2 strain is less likely to occur. The data collected from genomic sequencing can help pharmaceutical companies to stay ahead of the variants and make any changes needed to the current vaccines and treatments for higher efficacy and best patient outcomes. With PMLS’ high throughput genomic sequencers and library prep instruments that automate the library prep and sequencing process, a much higher capacity for genomic sequencing is achieved and margins of human error are drastically reduced. By sequencing an exponentially higher amount of specimens, PMLS is better equipped to provide meaningful analysis with larger amounts of data and faster turnaround times for the effective surveillance of SARS-CoV-2. PMLS is in discussions with the CDC and multiple states across the nation to provide COVID sequencing services at ports of entry and local and regional hotspots.  Along with this and their previous accomplishments, more groundbreaking COVID-19 solutions by Diversified Medical Healthcare are soon to be announced.

    For more information, please visit www.divmedinc.com or call 866-521-7541.